9780470169278

Biomarkers in Drug Development : A Handbook of Practice, Application, and Strategy

by ; ; ; ;
  • ISBN13:

    9780470169278

  • ISBN10:

    0470169273

  • Format: Hardcover
  • Copyright: 2010-02-15
  • Publisher: Wiley

Note: Supplemental materials are not guaranteed with Rental or Used book purchases.

Purchase Benefits

  • Free Shipping On Orders Over $35!
    Your order must be $35 or more to qualify for free economy shipping. Bulk sales, PO's, Marketplace items, eBooks and apparel do not qualify for this offer.
  • Get Rewarded for Ordering Your Textbooks! Enroll Now
List Price: $204.00 Save up to $20.40
  • Rent Book $183.60
    Add to Cart Free Shipping

    TERM
    PRICE
    DUE

Supplemental Materials

What is included with this book?

  • The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
  • The Rental copy of this book is not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

Summary

By focusing on how to identify, develop, and integrate biomarkers into drug development, this book will improve biomarker use and enhance pharmaceutical decision making. The coverage includes case studies showing how biomarkers can substantively impact drug development timelines and costs, enable better compound selection and reduce late stage attrition, and facilitate personalized medicine. It describes biomarker technologies, characterization and validation, and applications including in discovery, preclinical safety assessment, clinical trials, and translational medicine. The text, a useful resource for the pharmaceutical industry, also looks at practical issues and intellectual property concerns.

Author Biography

Michael R. Bleavins, PhD, is cofounder of Michigan Technology and Research Institute. He retired from Pfizer/Warner-Lambert/Parke-Davis in 2006 and has twenty-three years of experience in pharmaceutical research, development, and biomarkers with more than sixty-five peer-reviewed publications. Claudio Carini, MD, PhD, FRCPATH, is Chief Medical Officer and Vice President for Clinical Research at Fresenius. Previously, Claudio served as Global Head of Translational Medicine at MDS and Global Head of Biomarkers at Hoffmann-La Roche. Claudio has more than twenty years of experience in the field of immunology and biomarkers and has authored more than 200 publications in international and domestic peer-reviewed journals. Mall Jurima-Romet, PhD, is Senior Director for Development and Regulatory Services and MDS Pharma Services, where she provides strategic and scientific consulting to pharmaceutical and biotech sponsors, and leads drug development program teams. Mall has authored over forty peer-reviewed publications and is an adjunct professor at the University of Montreal. Ramin Rahbari, MS, is cofounder and Senior Consultant at Innovative Scientific Management. Previously, Ramin has held positions at Pfizer, Synaptic, and Parke-Davis pharmaceutical companies, leading cross-functional biomarker teams.

Table of Contents

Contributorsp. ix
Prefacep. xv
Biomarkers and Their Role in Drug Developmentp. 1
Biomarkers Are Not Newp. 3
Biomarkers: Facing the Challenges at the Crossroads of Research and Health Carep. 15
Enabling Go/No Go Decisionsp. 31
Identifying New Biomarkers: Technology Approachesp. 41
Imaging as a Localized Biomarker: Opportunities and Challengesp. 43
Protein Biomarker Discovery Using Mass Spectrometry-Based Proteomicsp. 101
Quantitative Multiplexed Patterning of Immune-Related Biomarkersp. 121
Gene Expression Profiles as Preclinical and Clinical Cancer Biomarkers of Prognosis, Drug Response, and Drug Toxicityp. 135
Use of High-Throughput Proteomic Arrays for the Discovery of Disease-Associated Moleculesp. 155
Characterization and Validationp. 177
Characterization and Validation Biomarkers in Drug Development: Regulatory Perspectivep. 179
Fit-for-Purpose Method Validation and Assays for Biomarker Characterization to Support Drug Developmentp. 187
Molecular Biomarkers from a Diagnostic Perspectivep. 215
Strategies for the Co-Development of Drugs and Diagnostics: FDA Perspective on Diagnostics Regulationp. 231
Importance of Statistics in the Qualification and Application of Biomarkersp. 247
Biomarkers in Discovery and Preclinical Safetyp. 287
Qualification of Safety Biomarkers for Application to Early Drug Developmentp. 289
Development of Serum Calcium and Phosphorus as Clinical Biomarkers for Drug-Induced Systemic Mineralization: Case Study with a MEK Inhibitorp. 301
Biomarkers for the Immunogenicity of Therapeutic Proteins and Its Clinical Consequencesp. 323
New Markers of Kidney Injuryp. 335
Translating from Preclinical Results to Clinical and Backp. 359
Translation Medicine-A Paradigm Shift in Modern Drug Discovery and Development: The Role of Biomarkersp. 361
Clinical Validation and Biomarker Translationp. 375
Predicting and Assessing an Inflammatory Disease and Its Complications: Example from Rheumatoid Arthritisp. 399
Pharmacokinetic and Pharmacodynamic Biomarker Correlationsp. 413
Validating In Vitro Toxicity Biomarkers Against Clinical Endpointsp. 433
Biomarkers in Clinical Trialsp. 443
Opportunities and Pitfalls Associated with Early Utilization of Biomarkers: Case Study in Anticoagulant Developmentp. 445
Integrating Molecular Testing Into Clinical Applicationsp. 463
Biomarkers for Lysosomal Storage Disordersp. 475
Value Chain in the Development of Biomarkers for Disease Targetsp. 485
Lessons Learned: Practical Aspects of Biomarker Implementationp. 493
Biomarkers in Pharmaceutical Development: The Essential Role of Project Management and Teamworkp. 495
Integrating Academic Laboratories into Pharmaceutical Developmentp. 515
Funding Biomarker Research and Development Through the Small Business Innovative Research Programp. 527
Novel and Traditional Nonclinical Biomarker Utilization in the Estimation of Pharmaceutical Therapeutic Indicesp. 541
Anti-Unicorn Principle: Appropriate Biomarkers Don't Need to Be Rare or Hard to Findp. 551
Biomarker Patent Strategies: Opportunities and Risksp. 565
Where Are We Heading and What Do We Really Need?p. 575
IT Supporting Biomarker-Enabled Drug Developmentp. 377
Redefining Disease and Pharmaceutical Targets Through Molecular Definitions and Personalized Medicinep. 593
Ethics of Biomarkers: The Borders of Investigative Research, informed Consent, and Patient Protectionp. 625
Pathodynamics: Improving Biomarker Selection by Getting More Information from Changes Over Timep. 643
Optimizing the Use of Biomarkers for Drug Development: A Clinician's Perspectivep. 693
Nanotechnology-Based Biomarker Detectionp. 709
Indexp. 731
Table of Contents provided by Ingram. All Rights Reserved.

Rewards Program

Write a Review